June 14, 2011

Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the folic acid for vascular outcome reduction in transplantation trial

.   .   

The FAVORIT study is the largest randomized controlled trial ever conducted in renal transplantation. It examined whether lowering homocysteine levels using folic acid, vitamin B6 and vitamin B12 would reduce cardiovascular events in a group of stable renal transplant patients. Although homocysteine levels were lowered, there was no difference in cardiovascular events, death or graft loss.

Related Articles:

Renal Transplantation

Comments are closed.